Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
Status:
Recruiting
Trial end date:
2028-09-30
Target enrollment:
Participant gender:
Summary
This research study is studying a new type of personalized neoantigen vaccine (NeoVax) plus
Montanide® in combination with Ipilimumab (Yervoy™) and Nivolumab (Opdivo®) as a possible
treatment for melanoma.
The drugs involved in this study are:
- Personalized Neoantigen Vaccine
- Poly-ICLC (Hiltonol®)
- Montanide®
- Ipilimumab (Yervoy™)
- Nivolumab (Opdivo®)